0001654954-23-013848.txt : 20231107 0001654954-23-013848.hdr.sgml : 20231107 20231107103048 ACCESSION NUMBER: 0001654954-23-013848 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 7 CONFORMED PERIOD OF REPORT: 20231106 FILED AS OF DATE: 20231107 DATE AS OF CHANGE: 20231107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: FSD Pharma Inc. CENTRAL INDEX KEY: 0001771885 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39152 FILM NUMBER: 231382243 BUSINESS ADDRESS: STREET 1: FIRST CANADIAN PLACE STREET 2: 100 KING STREET WEST, SUITE 4000 CITY: TORONTO STATE: A6 ZIP: M5X 1A4 BUSINESS PHONE: (416) 854-8884 MAIL ADDRESS: STREET 1: FIRST CANADIAN PLACE STREET 2: 100 KING STREET WEST, SUITE 4000 CITY: TORONTO STATE: A6 ZIP: M5X 1A4 6-K 1 fsd_6k.htm FORM 6-K fsd_6k.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________________________________________

 

FORM 6-K

________________________________________________________

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2023

 

Commission File Number: 001-39152

________________________________________________________

 

FSD PHARMA INC.

(Registrant)

________________________________________________________

 

199 Bay St., Suite 4000

Toronto, Ontario M5L 1A9 Canada

 (Address of Principal Executive Offices) 

________________________________________________________

 

Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  ☒            Form 40-F  ☐

 

Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

 

Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

FSD PHARMA INC.

 

(Registrant)

 

 

 

Date November 6, 2023

By

/s/ Nathan Coyle

 

Nathan Coyle

 

Chief Financial Officer

 

 

 
2

 

 

EXHIBIT INDEX

 

Exhibit

 

Description of Exhibit

99.1

 

News Release dated September 18, 2023 – FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis. The Report Shows Compound to be Safe and Well Tolerated

 

 

 

99.2

 

News Release dated October 4, 2023 – FSD Pharma Wins $2.8 Million Dollar Award Plus Accruing Interest from Dr. Raza Bokhari; Set Aside Motion Brought by Bokhari, Now CEO of Medicus Pharma, Dismissed by the Ontario Superior Court of Justice

 

 

 

99.3

 

News Release dated October 5, 2023 – FSD Pharma and Celly NU Enter into Arrangement Agreement

 

 
3

 

 EX-99.1 2 fsd_ex991.htm NEWS RELEASE fsd_ex991.htm

EXHIBIT 99.1

 

 

FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis. The Report Shows Compound to be Safe and Well Tolerated

 

Toronto, September 18, 2023 -- FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, today announced that an interim report has been received for the first-in-human (“FIH”) single ascending dose Phase I clinical trial evaluating the Company’s novel drug candidate Lucid-21-302 (“Lucid-MS”), an orally-administered treatment for Multiple Sclerosis (“MS”). This interim blinded report was issued on August 17, 2023 for the first 4 cohorts, with an addendum report describing the results of the fifth cohort due by the end of the month.

 

The report, issued by Biopharma Services Inc. as the clinical research organization under contract to FSD, states that “Lucid-21-302 was demonstrated to be safe and well-tolerated in single oral doses in healthy volunteers. Individual concentrations and PK parameters of Cohorts 1 to 4 are very encouraging for further development activity.”

 

“We are thrilled with the results described in this report, and consider this to be a major milestone for our team,” said Dr. Andrzej Chruscinski, Vice President Clinical and Scientific Affairs at Lucid Psycheceuticals, a wholly owned subsidiary of FSD Pharma. “We are looking forward to continuing the development of Lucid-MS for potential treatment of progressive MS, an indication where there is an unmet need for novel, non-immunomodulatory treatments.”

 

In Multiple Sclerosis, the brain, spinal cord, and optic nerves that make up the central nervous system (CNS) are attacked by immune system, and damage to CNS leads to the symptoms of MS. Secondary progressive multiple sclerosis is a course of the disease in which neurologic function worsens and disability increases, and typically follows the initial course of relapsing- remitting MS. According to estimates from the National Multiple Sclerosis Society, 27–45 for every 100,000 people in the United States have SPMS. According to the National Multiple Sclerosis Society, 10 to 15 percent of people with MS have primary progressive MS, an advanced disease course characterized by gradual worsening neurologic symptoms and an accumulation of disability. Clinically isolated syndrome, one of the 4 multiple sclerosis disease courses, is also due to demyelination, in addition to inflammation, and patients experience neurological symptoms due to damage to CNS. The current disease-modifying therapies work primarily by reducing inflammation in the CNS but are not very effective for the treatment of nerve degeneration.

 

 

 

 

Dr. Lakshmi P. Kotra, CEO of Lucid Psycheceuticals said, “Our objective in this FIH study was to determine the safety, tolerability, and pharmacokinetic profile of Lucid-MS in humans and we seem to have been successful in meeting those goals. Development of novel, non- immunomodulatory therapies with new mechanisms of action is a very high priority for all stages of MS. We are inspired to expeditiously pursue the next stages of clinical development to bring such novel therapies for patients.”

 

About FSD Pharma

 

FSD Pharma Inc. is a biotechnology company with two candidates in different stages of development. Lucid Psychss Inc., a wholly owned subsidiary, is focused on the research and development of its lead compounds, Lucid-MS and UNBUZZD™. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. UNBUZZD™ is a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of potentially quickly relieving from the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle.

 

Forward Looking Information

 

This press release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable securities laws. Any statements that are contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “plans”, “expects”, “expected”, “scheduled”, “estimates”, “intends”, “anticipates”, “hopes”, “planned” or “believes”, or variations of such words and phrases, or states that certain actions, events or results “may”, “could”, “would”, “might”, “potentially” or “will” be taken, occur or be achieved. More particularly, and without limitation, this press release contains forward-looking statements contained in this press release include statements concerning the future of FSD Pharma Inc. and are based on certain assumptions that FSD Pharma has made in respect thereof as of the date of this press release. FSD Pharma cannot give any assurance that such forward-looking statements will prove to have been correct.

 

Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. The Company cautions that although it believes the expectations and material factors and assumptions reflected in these forward-looking statements are reasonable as of the date hereof, there can be no assurance that these expectations, factors and assumptions will prove to be correct and these risks and uncertainties give rise to the possibility that actual results may differ materially from the expectations set out in the forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to a number of known and unknown risks and uncertainties including, but not limited to: the fact that the drug development efforts of both Lucid and FSD BioSciences are at a very early stage; the fact that preclinical drug development is uncertain, and the drug product candidates of Lucid and FSD BioSciences may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of Lucid and FSD BioSciences; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the potential inability to obtain or maintain regulatory approval of the drug product candidates of Lucid and FSD BioSciences; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of Lucid and FSD BioSciences; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected, or impacted by COVID-19 related issues; the potential inability to obtain adequate financing; the potential inability to obtain or maintain intellectual property protection for the drug product candidates of Lucid and FSD BioSciences; and other risks. Accordingly, readers should not place undue reliance on the forward-looking statements contained in this press release, which speak only as of the date of this press release.

 

 

 

 

Further information regarding factors that may cause actual results to differ materially are included in the Company’s annual and other reports filed from time to time with the Canadian Securities Administrators on SEDAR (www.sedar.com) and with the U.S. Securities and Exchange Commission on EDGAR (www.sec.gov), including the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2021, under the heading “Risk Factors.” This list of risk factors should not be construed as exhaustive. Readers are cautioned that events or circumstances could cause results to differ materially from those predicted, forecasted or projected. The forward- looking statements contained in this document speak only as of the date of this document. FSD Pharma does not undertake any obligation to publicly update or revise any forward-looking statements or information contained herein, except as required by applicable laws. The forward- looking statements contained in this document are expressly qualified by this cautionary statement.

 

Neither the Canadian Securities Exchange nor its regulation services provider accept responsibility for the adequacy or accuracy of this release.

 

Contacts

 

Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board, FSD Pharma Inc.

Email: Zsaeed@fsdpharma.com

Telephone: (416) 854-8884

 

Investor Relations:

Email: ir@fsdpharma.com, info@fsdpharma.com

Website: www.fsdpharma.com

 

ClearThink

Email: nyc@clearthink.capital

Telephone: (917) 658-7878

 

 

 

 EX-99.2 3 fsd_ex992.htm NEWS RELEASE fsd_ex992.htm

EXHIBIT 99.2

 

 

FSD Pharma Wins $2.8 Million Dollar Award Plus Accruing Interest from Dr. Raza Bokhari; Set Aside Motion Brought by Bokhari, Now CEO of Medicus Pharma, Dismissed by the Ontario Superior Court of Justice.

 

Toronto, October 4, 2023 -- FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, today announced that the Ontario Superior Court of Justice (the “Court”) has dismissed the motion to set aside the arbitration award to FSD Pharma filed by Dr. Raza Bokhari, the former CEO of FSD Pharma and current CEO of Medicus Pharma, Ltd. As disclosed in a press release on May 11, 2023 (https://feeds.issuerdirect.com/news- release.html?newsid=4924606685100137), the Honourable J. Douglas Cunningham, K.C. ruled in favor of FSD Pharma, awarding the Company approximately CDN$2.81 million in costs of arbitration between FSD Pharma and Dr. Bokhari. Dr. Bokhari challenged the ruling to arbitration without avail.

 

The Ontario Superior Court of Justice dismissed the set aside motion advanced by Dr. Raza Bokhari in its entirety. FSD Pharma brought a cross application for a judgment to enforce the awards. The Ontario Superior Court of Justice granted this motion.

 

The judgment cited many adequate reasons for FSD Pharma properly terminating Mr. Raza Bokhari for cause, one such reason cited being:

 

”In particular, by knowingly and flagrantly breaching the terms of the McEwen J. Judgment and the Hainey J. Injunction, in retaining and paying Santorum, by attempting to divert USD $12 million from FSD’s Canadian bank account to the Bryn Mawr account in the US over which he had control and by attempting to divert funds in the FSD Wheels Up account to his own use, Bokhari breached in a material way, material provisions of the Employment Agreement.”

 

Dr. Raza Bokhari tried to maintain that the arbitrator did not provide ample explanation why he was found to lack credibility. The Ontario Superior Court of Justice disagreed with this challenge and stated that the arbitrator “considered all of Bokhari’s explanations for his conduct in context and concluded that they were not believable.”

 

 

 

 

FSD Pharma is delighted with the Court’s decision and will vigorously pursue to collect the monetary awards of over CDN$2.8 million that were awarded by the arbitrator on May 07,2023 plus all accruing interest at a rate of 6%. In addition, the Court also ordered Bokhari to pay FSD Pharma $175,000 to cover its legal costs for his failed set aside motion. Dr. Bokhari was required to put up $150,000 as security for costs before the motion was heard, which he has forfeited. In addition, he is now expected to pay another $25,000 to FSD for the costs for this motion alone.

 

About FSD Pharma

 

FSD Pharma Inc. is a biotechnology company with two candidates in different stages of development. Lucid Psychss Inc., a wholly owned subsidiary, is focused on the research and development of its lead compounds, Lucid-MS and UNBUZZD™. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. UNBUZZD™ is a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of potentially quickly relieving from the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle.

 

Forward Looking Information

 

This press release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable securities laws. Any statements that are contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “plans”, “expects”, “expected”, “scheduled”, “estimates”, “intends”, “anticipates”, “hopes”, “planned” or “believes”, or variations of such words and phrases, or states that certain actions, events or results “may”, “could”, “would”, “might”, “potentially” or “will” be taken, occur or be achieved. More particularly, and without limitation, this press release contains forward-looking statements contained in this press release include statements concerning the future of FSD Pharma Inc. and are based on certain assumptions that FSD Pharma has made in respect thereof as of the date of this press release. FSD Pharma cannot give any assurance that such forward-looking statements will prove to have been correct.

 

Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. The Company cautions that although it believes the expectations and material factors and assumptions reflected in these forward-looking statements are reasonable as of the date hereof, there can be no assurance that these expectations, factors and assumptions will prove to be correct and these risks and uncertainties give rise to the possibility that actual results may differ materially from the expectations set out in the forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to a number of known and unknown risks and uncertainties including, but not limited to: the fact that the drug development efforts of both Lucid and FSD BioSciences are at a very early stage; the fact that preclinical drug development is uncertain, and the drug product candidates of Lucid and FSD BioSciences may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of Lucid and FSD BioSciences; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the potential inability to obtain or maintain regulatory approval of the drug product candidates of Lucid and FSD BioSciences; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of Lucid and FSD BioSciences; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected, or impacted by COVID-19 related issues; the potential inability to obtain adequate financing; the potential inability to obtain or maintain intellectual property protection for the drug product candidates of Lucid and FSD BioSciences; and other risks. Accordingly, readers should not place undue reliance on the forward-looking statements contained in this press release, which speak only as of the date of this press release.

 

 

 

 

Further information regarding factors that may cause actual results to differ materially are included in the Company’s annual and other reports filed from time to time with the Canadian Securities Administrators on SEDAR (www.sedar.com) and with the U.S. Securities and Exchange Commission on EDGAR (www.sec.gov), including the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2021, under the heading “Risk Factors.” This list of risk factors should not be construed as exhaustive. Readers are cautioned that events or circumstances could cause results to differ materially from those predicted, forecasted or projected. The forward- looking statements contained in this document speak only as of the date of this document. FSD Pharma does not undertake any obligation to publicly update or revise any forward-looking statements or information contained herein, except as required by applicable laws. The forward- looking statements contained in this document are expressly qualified by this cautionary statement.

 

Neither the Canadian Securities Exchange nor its regulation services provider accept responsibility for the adequacy or accuracy of this release.

 

Contacts

 

Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board, FSD Pharma Inc.

Email: Zsaeed@fsdpharma.com

Telephone: (416) 854-8884

 

Investor Relations:

Email: ir@fsdpharma.com, info@fsdpharma.com

Website: www.fsdpharma.com

 

ClearThink

Email: nyc@clearthink.capital

Telephone: (917) 658-7878

 

 

 

 EX-99.3 4 fsd_ex993.htm NEWS RELEASE fsd_ex993.htm

EXHIBIT 99.3

 

 

FSD PHARMA AND CELLY NU ENTER INTO ARRANGEMENT AGREEMENT

 

Toronto, October 5, 2023 -- FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, and Celly Nutrition Corp. (“Celly Nu”) announced today that they have entered into a definitive arrangement agreement dated October 4, 2023 (the “Agreement”) with respect to the distribution of a portion of FSD Pharma’s shareholdings of Celly Nu to certain securityholders of FSD Pharma (the “Transaction”).

 

The Agreement

 

Pursuant to the Agreement, the Company will recommend to the holders of class A multiple voting shares (“Class A Shares”), class B subordinate voting shares (“Class B Shares”), and warrants exercisable for the purchase of Class B Shares, provided the applicable warrant certificate entitles the holder thereof to receive distributions substantially similar to those received by holders of Class B Shares (“Class B Distribution Warrants”, collectively with the Class A Shares, and the Class B Shares, the “FSD Pharma Securities”) at an upcoming special meeting (the “Meeting”) to distribute common shares in the capital of Celly Nu (“Celly Shares”) to the holders of the FSD Pharma Securities (“FSD Pharma Securityholders”), on the basis of one Celly Share distributed in respect of each FSD Pharma Security that is issued and outstanding as of the final record date for the Transaction (the “Distribution Record Date”). The Company expects that this will result in an aggregate of approximately 45,714,621 Celly Shares being distributed to the FSD Pharma Securityholders (the “Distributed Shares”) and an aggregate of approximately 154,285,379 Celly Shares retained by the Company, in each case assuming that the number of FSD Pharma Securities remains unchanged between today and the Distribution Record Date.

 

Subject to the approval of the FSD Pharma Securityholders, the Transaction will be effected by way of a court approved plan of arrangement (“Plan of Arrangement”) under the provisions of the Business Corporations Act (Ontario). The Distribution Record Date will be announced promptly following receipt of the requisite approval of the FSD Pharma Securityholders and regulatory approvals. There will be no change in FSD Pharma Securityholders’ proportionate ownership in FSD Pharma Securities as a result of the Plan of Arrangement. In addition, holders of FSD Pharma options (“FSD Options”) and non-distribution warrants (“Non-Distribution Warrants”) as at the effective date of the Plan of Arrangement will have such FSD Options and Non-Distribution Warrants adjusted in accordance with their terms as a result of the Transaction.

 

 

 

 

The Meeting and Closing Conditions

 

The meeting of the FSD Pharma Securityholders to consider and vote upon a special resolution (the “Arrangement Resolution”) approving the Plan of Arrangement will be held virtually on November 20, 2023, at 1:00 p.m. (Toronto time) (the “Meeting”). Further information concerning the Plan of Arrangement and the Meeting will be provided in subsequent news releases, and the management information circular of the Company which will be filed on SEDAR+.

 

Closing of the Transaction is subject to a number of conditions, including (i) approval of the FSD Pharma Securityholders at the Meeting; (ii) court approval of the Plan of Arrangement; and (iii) certain other customary conditions as further set out in the Agreement. FSD Pharma Securityholders are cautioned that final details of the Plan of Arrangement are subject to change and that there is no certainty that the Transaction will be completed as currently proposed or at all.

 

About FSD Pharma

 

FSD Pharma Inc. is a biotechnology company with two candidates in different stages of development. Lucid Psychss Inc., a wholly owned subsidiary, is focused on the research and development of its lead compounds, Lucid-MS and UNBUZZD™. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. UNBUZZD™ is a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of potentially quickly relieving from the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle.

 

About Celly Nu

 

Celly Nu is a pre-revenue, early-stage research and development company that intends on developing and manufacturing consumer products in the dietary supplement industry. Celly Nu is primarily focused on developing its business through certain intellectual property assets to create recreational and consumer prototype products that are expected to alleviate inebriation due to excessive alcohol consumption.

 

 

 

 

Cautionary Note Regarding Forward-Looking Information

 

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. “Forward-looking information” includes, but is not limited to, statements with respect to the completion of the Agreement and the Transaction; the anticipated timing of the Meeting, closing of the Transaction; the anticipated benefits of the Plan of Arrangement for FSD Pharma Securityholders; the satisfaction or waiver of the closing conditions set out in the Agreement, including receipt of all regulatory approvals; and the satisfaction final approval of the Agreement by the Canadian Securities Exchange and other activities, events or developments that the Company or Celly Nu expects or anticipates will or may occur in the future. Generally, but not always, forward-looking information and statements can be identified by the use of words such as “plans”, “expects”, “intends”, “estimates”, “intends”, “anticipates”, or “believes” or the negative connotation thereof or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative connotation thereof. Such forward-looking information and statements are based on numerous assumptions, including the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary regulatory, court and shareholder approvals; the ability of the parties to satisfy, in a timely manner, the other conditions to the completion of the Agreement and the Transaction; that general business and economic conditions will not change in a material adverse manner. Although the assumptions made by the Company or Celly Nu in providing forward-looking information or making forward-looking statements are considered reasonable by management at the time, there can be no assurance that such assumptions will prove to be accurate. Forward-looking information and statements also involve known and unknown risks and uncertainties and other factors, which may cause actual events or results in future periods to differ materially from any projections of future events or results expressed or implied by such forward-looking information or statements, including, among others: the diversion of management time on Transaction-related issues; reliance on key management and other personnel; potential downturns in economic conditions; actual, and risks generally associated with the biotechnology or nutritional supplement industry, changes in laws and regulations, community relations and delays in obtaining governmental or other approvals.

 

Although the Company and Celly Nu have attempted to identify important factors that could cause actual results to differ materially from those contained in the forward-looking information or implied by forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking statements or information. The Company or Celly Nu undertakes no obligation to update or reissue forward- looking information as a result of new information or events except as required by applicable securities laws. Additional information relating to FSD Pharma, including its annual information form, can be located on the SEDAR website at www.sedar.com and on the EDGAR section of the SEC's website at www.sec.gov.

 

None of the securities to be issued pursuant to the Transaction have been or will be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and any securities issuable in the Transaction are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Section 3(a)(10) of the U.S. Securities Act and applicable exemptions under state securities laws.

 

 

 

 

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities.

 

For further information:

 

FSD Pharma Inc.

 

Zeeshan Saeed, Founder, Chief Executive Officer and Executive Co-Chairman of the Board

Email: Zsaeed@fsdpharma.com

Telephone: (416) 854-8884

Investor Relations: Email: ir@fsdpharma.com , skilmer@fsdpharma.com

Website: www.fsdpharma.com

 

Celly Nutrition Corp.

 

John Duffy, Chief Executive Officer

Email: johnduffy@cellynutrition.com

Telephone: 508-479-4923

Website: www.cellynutrition.com

 

 

 

 GRAPHIC 5 fsd_ex991img2.jpg begin 644 fsd_ex991img2.jpg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fsd_ex993img2.jpg begin 644 fsd_ex993img2.jpg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fsd_ex992img2.jpg begin 644 fsd_ex992img2.jpg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end